105184-37-0

Splenopentin (1-100 μM) augments human NK cells and has no cytotoxicity.
Splenopentin (0.1 ng/mL-10 μg/mL; 3 h) induces phenotypic differentiation of both T- and B -cell precursor cells.

Splenopentin (1 mg/kg; ip three times a week for 7-90 d) accelerates Langerhans cell recruitment and leads to pretreatment levels of Langerhans cell (LC) density in the skin of mice.
Splenopentin (0.01-100 μg per mouse; ip) has no demonstrable effect on neuromuscular transmission of mice.